

to examine the biochemical functions of the brain in which the various positron-labeled tracer substances are involved.

The PET scan presently is strictly a research tool, though it may have applications in clinical psychiatry in the future. To date most studies have involved substances like water  $^{15}\text{O}$  to look at blood flow or fluorodeoxyglucose  $^{18}\text{F}$  to look at glucose metabolism. A few studies have been done using labeled drugs, most notably spiroperidol, which binds to and thus allows localization of dopamine receptors.

PET studies of glucose metabolism are already yielding interesting findings in cases of major psychiatric illness. In patients with chronic schizophrenia, glucose metabolism in the frontal lobes appears low when compared with that of posterior brain regions. This pattern is the reverse of that seen in normal persons. In mood disorders one group reports that patients with bipolar (manic-depressive) depression have low metabolic rates in all supratentorial brain structures when compared with normal persons, patients with bipolar depression who are in a manic state and even those with unipolar depression. In contrast, patients with unipolar depression show a decrease in the metabolic rate of the caudate nucleus relative to that of the person's brain as a whole. In another study, using water  $^{15}\text{O}$  to study blood flow, those patients with panic disorder in whom an infusion of sodium lactate causes a panic attack were shown to have a decrease in blood flow to the left hippocampal gyrus compared with that on the right. These two interesting studies await replication.

LEWIS R. BAXTER, Jr, MD  
Los Angeles

#### REFERENCES

- Baxter LR, Phelps ME, Mazziotta JC, et al: Cerebral metabolic rates for glucose in mood disorders studied with positron emission tomography (PET) and (F-18) fluorodeoxyglucose (FDG). *Arch Gen Psychiatry*, in press
- Buchsbaum MD, Ingvar DH, Kessler R, et al: Cerebral glucography with positron tomography—Use in normal subjects and in patients with schizophrenia. *Arch Gen Psychiatry* 1982 Mar; 39:251-259
- Phelps ME, Mazziotta JC, Huang SC: Study of cerebral function with positron computed tomography. *J Cereb Blood Flow Metab* 1982; 2(2):113-162
- Reiman EM, Raichle ME, Butler FK, et al: A focal brain abnormality in panic disorder, a severe form of anxiety. *Nature* 1984 Aug 23-29; 310:683-685
- Wagner HN Jr, Burns HD, Dannals RF, et al: Imaging dopamine receptors in the human brain by positron tomography. *Science* 1983 Sep 23; 221:1264-1266

## Use of Carbamazepine in Mood Disorders

CARBAMAZEPINE (TEGRETOL) is used extensively to treat partial complex (psychomotor or temporal lobe) and major motor (grand mal) seizures. In the past few years, carbamazepine has been shown to have value in treating cases of bipolar (manic-depressive) disorders. In studies carried out first in Japan and then in this country this drug has been remarkably effective both in treating patients with manic episodes and for maintenance to prevent recurrences. Its efficacy is on a par with that of lithium carbonate and many patients who do not respond to or cannot tolerate lithium can be effectively treated with carbamazepine. At present, it is usually only used in such patients. Carbamazepine may be effective in treating patients with depression, both bipolar and unipolar, though this is less well documented than its effects in cases of mania.

Treatment begins with 100 or 200 mg given twice a day, which increases, as patient tolerance permits, to a total of 600 to 1,600 mg a day (average dose about 1,000 mg a day). Carbamazepine blood concentrations do not correlate with

therapeutic response in bipolar illness. Carbamazepine is compatible with most other psychiatric drugs. Some patients have required treatment with both carbamazepine and lithium to get an adequate response, though there are reports of occasional central neurotoxicity.

Carbamazepine is closely related to the tricyclic antidepressants and should not be added to the regimen of a patient already taking a monoamine-oxidase inhibitor. As with other tricyclics, monoamine-oxidase inhibitors can be added once a person is taking carbamazepine.

Many physicians have been unduly frightened about carbamazepine because of early reports of aplastic anemia occurring. Most of these cases were in elderly patients with numerous medical problems being treated with many drugs. Despite the increasing use of carbamazepine by neurologists and psychiatrists, there has not been a corresponding increase in cases of aplastic anemia related to its use. Side effects with the use of carbamazepine consist of those that can be seen with tricyclic antidepressants, but, in addition, there seems to be an increased incidence of dizziness (often true vertigo), pruritic rash and a mild lowering of the leukocyte count. Liver toxicity rarely occurs.

LEWIS R. BAXTER, Jr, MD  
Los Angeles

#### REFERENCES

- Kishimoto A, Ogura C, Hazama H, et al: Long-term prophylactic effects of carbamazepine in affective disorder. *Br J Psychiatry* 1983 Oct; 143:327-331
- Nolen WA: Carbamazepine, a possible adjunct or alternative to lithium in bipolar disorder. *Acta Psychiatr Scand* 1983 Apr; 67:218-225
- Post RM, Ballenger JC, Uhde TW, et al: Efficacy of carbamazepine in manic-depressive illness: Implications for underlying mechanisms, chap 50. In Post RM, Ballenger JC (Eds): *Neurobiology of Mood Disorders*. Baltimore, Williams & Wilkins, 1984, pp 777-816
- Shukla S, Godwin CD, Long LEB, et al: Lithium-carbamazepine neurotoxicity and risk factors. *Am J Psychiatry* 1984 Dec; 141:1604-1606

## Update on Electroconvulsive Therapy

ELECTROCONVULSIVE THERAPY remains a viable and important treatment in psychiatry. In California, for example, some 2,600 patients receive it each year (in spite of the strict legal requirements in the state).

More than a dozen different antidepressants are available in the United States, yet many patients with major depression respond only to electroconvulsive treatment. Response rates in the order of 70% to 90% have been shown. In some cases of severe life-threatening depression or in patients who are severely ill medically, electroconvulsive therapy is the treatment of choice. Manic patients who are not responsive to conventional treatments have about a 90% response rate to this treatment. Although manic exhaustion and depressive inanition were once common causes of death, today they are quite rare. Schizophrenic patients in acute stages who are unresponsive to standard treatments or who have experienced severe side effects, such as agranulocytosis or severe tardive dyskinesia, have a 75% response rate with electroconvulsive therapy. It is extremely safe, with a mortality rate of only 0.2 deaths per 10,000 treatments in California from 1977 to 1983.

There are virtually no absolute medical contraindications to electroconvulsive therapy. Although a brain tumor or a recent myocardial infarction are generally considered contra-